U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07414602) titled 'A Phase I Study of Single Subcutaneous Dose of SHR-1894 in Healthy Subjects' on Feb. 03.
Brief Summary: The Phase I clinical study aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-1894 in healthy subjects.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Dermatitis
Intervention:
DRUG: SHR-1894 Injection
SHR-1894 injection.
DRUG: SHR-1894 Injection Placebo
SHR-1894 injection placebo.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....